Detailed Notes on ABBV-744 BRD4 inhibitor mechanism of action
In Section C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until finally disorder progression or even the members are unable to tolerate the study drugs.- Participant eaten grapefruit or grapefruit products within three days prior to the first d